Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "leukemia" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 49
Tytuł:
Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells
Autorzy:
Wu, Yao-Hui
You, Yong
Chen, Zhi-Chao
Zou, Ping
Powiązania:
https://bibliotekanauki.pl/articles/1040668.pdf
Data publikacji:
2008
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
chemotherapeutic resistance
Survivin
acute myeloid leukemia
shRNA
apoptosis
Opis:
The role of Survivin in the pathogenesis of leukemia was explored in order to discover the effective avenues for gene therapy. Most primary leukemia cells isolated from patients as well as three leukemia cell lines (HL-60, K562, and U937) all expressed Survivin gene. To investigate the relationship between Survivin and chemotherapeutic resistance, HL-60 cells were treated with daunorubicin (DNR), mitoxantrone (MIT) or arsenious oxide (As2O3), and it was found that after 24 h the level of Survivin mRNA was decreased by 9.7%, 41.0% and 27.5%, respectively. At 72 h, the level of Survivin mRNA was increased by 21.2% and 65.2% in HL-60 cells treated with DNR or MIT, but decreased by 33.2% in those treated with As2O3 as compared with that in the cells treated for 24 h. These results showed that DNR and MIT could initally decrease the expression of Survivin and then increase it, but As2O3 could decrease the Survivin expression continually. Furthermore, shRNA plasmids targeting the Survivin gene (pEGFP-Survivin), which can silence the expression of Survivin with a high specificity, were constructed. pEGFP-Survivin and pEGFP-H1 were transfected into HL-60 cells via electroporation and selected by G418, and HL-60/Survivin and HL-60/EGFP cells were obtained. After treatment with DNR, the cell survival rate and IC50 of DNR in HL-60/Survivin cells were decreased substantially as compared with those of HL-60/EGFP and HL-60 cells (IC50 of DNR: 18.3 ± 2.45 vs 40.8 ± 6.37 and 39.2 ± 5.91 ng/ml, respectively), and the apoptosis rate was elevated ((84.3 ± 19.7)% vs (45.8 ± 13.8)% and (50.9 ± 12.4)%, respectively). These results suggest that shRNA can down-regulate the expression of Survivin in HL-60 cells substantially and improve their sensitivity to DNR. They also further explain the pathogenesis of leukemia drug resistance and provide new theory in the design of clinical therapies.
Źródło:
Acta Biochimica Polonica; 2008, 55, 4; 673-680
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Molecular hematology – modern methodology serving patients and research
Autorzy:
Witt, Michał
Powiązania:
https://bibliotekanauki.pl/articles/703644.pdf
Data publikacji:
2009
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
allogenic transplantation of hematopoetic stem cells
leukemia
lymphoma
minimal residual disease
posttransplant chimerism
Opis:
The article describes a country-wide attempt to organize a network of laboratories performing molecular diagnostic procedures in a context of clinical hematology. The principles of construction of a commissioned grant in molecular hematology are presented. A major result of this project, the monographic book on molecular hematology is being announced.
Źródło:
Nauka; 2009, 4
1231-8515
Pojawia się w:
Nauka
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin - prelimary results
Autorzy:
Wasik-Szczepanek, E.
Szymczyk, A.
Kowal, M.
Nogalski, A.
Hus, M.
Powiązania:
https://bibliotekanauki.pl/articles/2081565.pdf
Data publikacji:
2018
Wydawca:
Instytut Medycyny Wsi
Tematy:
chronic lymphocytic leukemia
ofatumumab
monoclonal antibodies
immunotherapy
Opis:
Introduction. Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases of the disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeutic options. Objective. Retrospective analysis of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia (CLL) treated in the Haematooncology and Bone Marrow Transplantation Department of the Medical University of Lublin, Poland, during 2011–2013. Materials and method. The analysis included 5 patients (3 women and 2 men), aged 47–65, with Rai stage II-IV CLL, after a few lines of treatment. Three patients received ofatumumab in monotherapy and 2 patients received ofatumumab in combination with cyclophosphamide (50 mg/day) and dexamethasone (40 mg/day). All patients included in the study were diagnosed with an active form of leukaemia with symptoms such as lymphocytosis or massive lymphadenopathy. Results. All patients responded to the treatment. Within the first 8 weeks of the treatment, levels of white blood cells returned to normal in patients with baseline lymphocytosis (3 patients). An increase in platelet levels was reported in 3 patients. Haemoglobin levels were higher or comparable to the baseline values in all studied patients after the completion of immunotherapy. In the patient with massive lymphadenopathy and hepato- and splenomegaly, the size of the lymph nodes, spleen and liver decreased and neutrophil levels increased. Time of progression was 5–12 months, and in one patient partial remission has been maintained. The treatment was well-tolerated in most cases. Asymptomatic neutropenia and an infection with Candida glabrata were observed. Conclusions. Ofatumumab may be a new and safe therapeutic option for patients with CLL after a few lines of treatment.
Źródło:
Annals of Agricultural and Environmental Medicine; 2018, 25, 1; 56-59
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Rare case of Richter’s syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) - case report and literature
Autorzy:
Wasik-Szczepanek, E.
Szymczyk, A.
Szczepanek, D.
Grywalska, E.
Szumiło, J.
Trojanowski, P.
Czabak, O.
Hus, M.
Powiązania:
https://bibliotekanauki.pl/articles/2085452.pdf
Data publikacji:
2020
Wydawca:
Instytut Medycyny Wsi
Tematy:
liver
thyroid
chronic lymphocytic leukemia
Richter’s syndrome
Opis:
Richter’s syndrome (RS) is a rare complication in which chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) transforms into a more aggressive type of lymphoma – diffuse large B cell lymphoma (DLBCL), or Hodgkin’s lymphoma (HL). The review describes the clinical case of a patient with CLL and RS diagnosis. A computed tomography (CT) scan of the abdominal cavity detected numerous normodense areas in the liver. Simultaneously, ultrasound examination (USG) of the thyroid revealed the presence of a solid hypoechogenic lump. The material sampled from closed biopsies of liver and thyroid in both cases allowed the diagnosis of diffuse large B cell lymphoma (DLBCL). The liver and the thyroid are particularly rare locations of RS. However, those cases allowed the conclusion that RS may occur even in a very unexpected and less probable location.
Źródło:
Annals of Agricultural and Environmental Medicine; 2020, 27, 1; 160-164
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cytotoxic effect of nitric oxide on human hematological malignant cells.
Autorzy:
Tsumori, Michihiro
Tanaka, Junko
Koshimura, Kunio
Kawaguchi, Mikiko
Murakami, Yoshio
Kato, Yuzuru
Powiązania:
https://bibliotekanauki.pl/articles/1043819.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
lymphoma
myeloma
leukemia
nitric oxide
Opis:
We investigated the cytotoxic effect of nitric oxide (NO) on primary culture of human hematological malignant cells. Sodium nitroprusside (SNP), an NO donor, had cytotoxic effects on the cells of some patients with malignant lymphoma (ML), acute myelocytic leukemia (AML) or chronic myelomonocytic leukemia (CMMoL), but not with multiple myeloma. Cultured cells from the ML patient remained sensitive to SNP after the cells became resistant to anti-cancer drugs. In contrast, the cells from the patients with AML and CMMoL became resistant to SNP while anti-cancer drugs remained effective. In samples of the cells of the patients with ML and AML, the number of CD3 positive lymphoma cell was decreased by SNP and the number of CD33 negative cells and normal B lymphocytes (CD19 positive cells) were increased. In the cells of the patient with ML, apoptosis was induced by SNP. SNP had no effect on lymphocytes of healthy volunteers. These results suggest that SNP had an anti-tumor effect on human hematological malignant cells.
Źródło:
Acta Biochimica Polonica; 2002, 49, 1; 139-144
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
Autorzy:
Telegeev, Gennady
Dubrovska, Anna
Dybkov, Mykhaylo
Maliuta, Stanislav
Powiązania:
https://bibliotekanauki.pl/articles/1041568.pdf
Data publikacji:
2004
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
Philadelphia chromosome
actin cytoskeleton
leukemia
BCR/ABL gene
Opis:
The hallmark of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL) is the presence of the Philadelphia chromosome as a result of the t(9;22) translocation. This gene rearrangement results in the production of a novel oncoprotein, BCR/ABL, a constitutively active tyrosine kinase. There is compelling evidence that the malignant transformation by BCR/ABL is critically dependent on its Abl tyrosine kinase activity. Also the bcr part of the hybrid gene takes part in realization of the malignant phenotype. We supposed that additional mutations accumulate in this region of the BCR/ABL oncogene during the development of the malignant blast crisis in CML patients. In ALL patients having p210 fusion protein the mutations were supposed to be preexisting. Sequencing of PCR product of the BCR/ABL gene (Dbl, PH region) showed that along with single-nucleotide substitutions other mutations, mostly deletions, had occurred. In an ALL patient a deletion of the 5th exon was detected. The size of the deletions varied from 36 to 220 amino acids. For one case of blast crisis of CML changes in the character of actin organization were observed. Taking into account the functional role of these domains in the cell an etiological role of such mutations on the disease phenotype and leukemia progression is plausible.
Źródło:
Acta Biochimica Polonica; 2004, 51, 3; 845-849
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Myeloid sarcoma associated with blast crisis in chronic myelogenous leukemia - case report
Autorzy:
Szymczyk, Agnieszka
Podhorecka, Monika
Tomczak, Waldemar
Szumiło, Justyna
Hus, Marek
Powiązania:
https://bibliotekanauki.pl/articles/972387.pdf
Data publikacji:
2016
Wydawca:
Instytut Medycyny Wsi
Tematy:
myeloid sarcoma
chronic myelogenous leukemia
blast crisis
Opis:
Introduction. Myeloid sarcoma (MS) is a rare extramedullary tumour which may precede or occur concomitantly with bone marrow involvement in acute myeloid leukemia, myelodysplastic syndrome, or blast crisis in chronic myeloproliferative disorder. Myeloid sarcoma is most commonly found in lymph nodes, skin, subcutaneous tissue and gums, while it is less common in bones, the retroperitoneal space and eye socket. Case Report. The case is reported of a 65-year-old woman with chronic myelogenous leukemia treated for about 20 years with hydroxyurea, 6-mercaptopurine and tyrosine-kinase inhibitors. During the treatment, the general condition of the patient progressively deteriorated, lymphadenopathy and splenomegaly worsened, and blast crisis was diagnosed. After the first cycle of induction chemotherapy, the patient’s lymph nodes were swollen and painful. One of the lymph nodes was subjected to histopathology, on the basis of which a diagnosis of MS was made. As the patient showed no response to the treatment, palliative care was initiated. Three months after the diagnosis of MS, the disease progressed. The patient died of infectious complications. Conclusions: A diagnosis of MS, which is considered an adverse prognostic factor, significantly reduces the chances of remission and overall survival in patients with acute myelogenous leukemia or blast crisis inchronic myeloproliferative disorders. It seems that early confirmation of the diagnosis and initiation of the treatment adjusted to the patient’s clinical condition may improve the prognosis and increase the response rates.
Źródło:
Journal of Pre-Clinical and Clinical Research; 2016, 10, 2; 136-139
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Partial remission in patient with Richter syndrome: an „emergency” treatment with pixantrone
Autorzy:
Szwedyk, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/1035640.pdf
Data publikacji:
2020-06-30
Wydawca:
Medical Education
Tematy:
Richter syndrome
chemotherapy
chronic lymphocytic leukemia
immunotherapy
pixantrone
Opis:
Chronic lymphocytic leukemia is the most commonly recognized type of leukemia in adults. The appearance of systemic symptoms such as weight loss, fever, or local symptoms in the form of rapidly growing organomegaly, lymphadenopathy in a patient with CLL raises the suspicion of transformation into a high-grade lymphoma – defined as Richter syndrome which is usually associated with very poor prognosis. The described case concerns a 71-year-old patient with this diagnosis, in whom due to the confirmed resistance to subsequent lines of immuno- and chemotherapy, an „emergency” treatment with a modern chemotherapy drug from the aza-anthracendion group – pixantrone was used. Treatment with pixantrone was associated with a relatively good response, translating into partial remission (also in the area of infiltrative changes in the head and neck structures), stabilization of the course of the disease and, consequently, allowed to extend the patient’s life.
Źródło:
OncoReview; 2020, 10, 2; 52-56
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Chemioterapia w ciąży
Chemotherapy during pregnancy
Autorzy:
Sznurkowski, Jacek J.
Klasa-Mazurkiewicz, Dagmara
Kobierski, Juliusz
Wydra, Dariusz
Emerich, Janusz
Powiązania:
https://bibliotekanauki.pl/articles/1030942.pdf
Data publikacji:
2010
Wydawca:
Medical Communications
Tematy:
cervical cancer
chemotherapy
pregnancy breast cancer
leukemia
białaczka
chemioterapia
ciąża
rak piersi
rak szyjki macicy
Opis:
Chemotherapy in the treatment of malignant tumors in pregnant women potentially threatens life and development of the fetus. Aim of paper: The purpose of this paper was to update current knowledge concerning the role of chemotherapy in combination therapy of gynecologic malignancies complicating pregnancy and to review available literature focusing on potential sequels of administration of chemotherapeutics at different time-points in pregnancy, with particular emphasis on fetal development, course of pregnancy and future lot of the child. Method: The PubMed database was searched using the following key words: methotrexate; 5-fluorouracil; aminopterin; thioguanine; mercaptopurine; cyclophosphamide; busulfan; ifosfamide; chlorambucil; dacarbazine; doxorubicin; daunorubicin; adriamycin; idarubicin; epirubicin; dactinomycin; bleomycin; mitoxantrone; vincristine; vinblastine; vinorelbine; paclitaxel; docetaxel; cisplatin; carboplatin; prednisone; tamoxifen; etoposide; teniposide; allopurinol; malformation; IUGR; chemotherapy; pregnancy. Search criteria were fulfilled by 33 papers (selected chemotherapeutic agent/pregnancy/malformation), which subsequently underwent content-related analysis. Conclusions: A decision on the use of chemotherapy during pregnancy should be made depending on type and stage of malignancy. It at all possible, administration of cytostatics should be delayed until the end of first trimester. If the patient requires multidrug therapy in the first trimester, she should receive anthracycline-derived antibiotics combined with Vinca alkaloids or should be placed on monotherapy and after 12 weeks shift to a multidrug regimen. Delivery should be planned for the 35th gestational week and 2-3 weeks after termination of chemotherapy in order to allow recovery of bone-marrow function.
Chemioterapia w leczeniu nowotworów złośliwych u kobiet w ciąży stanowi potencjalne zagrożenie dla życia i rozwoju płodu. Celem pracy było przybliżenie wiedzy na temat udziału chemioterapii w leczeniu skojarzonym nowotworów ginekologicznych wikłających ciążę oraz dokonanie przeglądu doniesień medycznych pod kątem skutków zastosowania poszczególnych czynników chemioterapeutycznych w różnych trymestrach ciąży, ze szczególnym uwzględnieniem wpływu na rozwój płodu, przebieg ciąży i dalsze losy dziecka. Metoda: Przy użyciu słów kluczowych: methotrexate; 5-fluorouracil; aminopterin; thioguanine; mercaptopurine; cyclophosphamide; busulfan; ifosfamide; chlorambucil; dacarbazine; doxorubicin; daunorubicin; adriamycin; idarubicin; epirubicin; dactinomycin; bleomycin; mitoxantrone; vincristine; vinblastine; vinorelbine; paclitaxel; docetaxel; cisplatin; carboplatin; prednisone; tamoxifen; etoposide; teniposide; allopurinol; malformation; IUGR; chemotherapy; pregnancy przeszukano bazę PubMed. Odnaleziono 33 artykuły anglojęzyczne spełniające kryteria wyszukiwania (wybrany czynnik chemioterapeutyczny/ciąża/malformacja), które poddano analizie merytorycznej. Wnioski: Decyzję o chemioterapii w ciąży należy podjąć stosownie do rodzaju nowotworu i jego stopnia zaawansowania klinicznego. Jeśli jest to tylko możliwe, należy odroczyć podawanie cytostatyków do końca pierwszego trymestru. W sytuacji, w której pacjentka wymaga terapii wielolekowej w pierwszym trymestrze, należy rozważyć zastosowanie antybiotyków antracyklinowych w połączeniu z alkaloidami Vinca lub rozpocząć leczenie terapią jednolekową i po 12 tygodniach przejść na schemat wielolekowy. Poród powinien być zaplanowany na 2 do 3 tygodni po zakończeniu chemioterapii, w celu umożliwienia powrotu prawidłowej czynności szpiku (około 35. tygodnia).
Źródło:
Current Gynecologic Oncology; 2010, 8, 2; 123-131
2451-0750
Pojawia się w:
Current Gynecologic Oncology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cross-resistance to five glucocorticoids in childhood acute lymphoblastic and non-lymphoblastic leukemia samples tested by the MTT assay: Preliminary report.
Autorzy:
Styczyński, Jan
Wysocki, Mariusz
Dębski, Robert
Balwierz, Walentyna
Rokicka-Milewska, Roma
Matysiak, Michał
Balcerska, Anna
Kowalczyk, Jerzy
Wachowiak, Jacek
Sońta-Jakimczyk, Danuta
Chybicka, Alicja
Powiązania:
https://bibliotekanauki.pl/articles/1043813.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
cross-resistance
ALL
sensitivity
acute leukemia
MTT assay
AML
glucocorticoid resistance
Opis:
In vitro antileukemic activity of five glucocorticoids and their cross-resistance pattern in childhood acute lymphoblastic and non-lymphoblastic leukemia were determined by means of the MTT assay in 25 leukemia cell samples of childhood acute leukemias. The equivalent antileukemic concentrations of the drugs tested were: 34 μM hydrocortisone (HC), 8 μM prednisolone (PRE), 1.5 μM methylprednisolone (MPR), 0.44 μM dexamethasone (DX) and 0.22 μM betamethasone (BET). In comparison with initial ALL cell samples, the relapsed ALL group was more resistant to PRE (38-fold, p = 0.044), DX (> 34-fold, p = 0.04), MPR (38-fold), BET (45-fold) and HC (33-fold). The AML cell samples were even more resistant to: PRE (>85-fold, p=0.001), DX (> 34-fold, p = 0.004), MPR (> 69-fold, p = 0.036), BET (> 69-fold, p = 0.038) and HC (54-fold, p = 0.059) when compared with ALL on initial diagnosis. A significant cross-resistance among all the glucocorticoids used was found. Only in some individual cases the cross-resistance was less pronounced.
Źródło:
Acta Biochimica Polonica; 2002, 49, 1; 93-98
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
In vitro activity of oxazaphosphorines in childhood acute leukemia: Preliminary report.
Autorzy:
Styczyński, Jan
Wysocki, Mariusz
Dębski, Robert
Balwierz, Walentyna
Rokicka-Milewska, Roma
Matysiak, Michał
Balcerska, Anna
Kowalczyk, Jerzy
Wachowiak, Jacek
Sońta-Jakimczyk, Danuta
Chybicka, Alicja
Powiązania:
https://bibliotekanauki.pl/articles/1043830.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
ALL
leukemia
sensitivity
glufosfamide
resistance
Opis:
Glufosfamide (β-D-glucosyl-ifosfamide mustard) is a new agent for cancer chemotherapy. Its pharmacology is similar to commonly used oxazaphosphorines, but it does not require activation by hepatic cytochrome P-450 and preclinically demonstrates lower nephrotoxicity and myelosuppression than ifosfamide. The aim of the study was a comparison of the drug resistance profiles of glufosfamide and other oxazaphosphorines in childhood acute leukemias. Leukemic cells, taken from children with ALL on diagnosis (n = 41), ALL on relapse (n = 12) and AML on diagnosis (n= 13) were analyzed by means of the MTT assay. The following drugs were tested: glufosfamide (GLU), 4-HOO-ifosfamide (IFO), 4-HOO-cyclophosphamide (CYC) and mafosfamide cyclohexylamine salt (MAF). In the group of initial ALL samples median cytotoxicity values for GLU, IFO, CYC and MAF were 15.5, 33.8, 15.7 and 7.8 μM, respectively. In comparison with initial ALL samples, the relative resistance for GLU and IFO in relapsed ALL samples was 1.9 (p = 0.049) and 1.3 (ns), and in initial AML samples 31 (p < 0.001) and 5 (p = 0.001), respectively. All oxazaphosphorines presented highly significant cross-resistance. Glufosfamide presented high activity against lymphoblasts both on diagnosis and on relapse.
Źródło:
Acta Biochimica Polonica; 2002, 49, 1; 221-225
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Autorzy:
Styczyński, Jan
Wysocki, Mariusz
Dębski, Robert
Kurylak, Andrzej
Balwierz, Walentyna
Rokicka-Milewska, Roma
Matysiak, Michał
Balcerska, Anna
Kowalczyk, Jerzy
Wachowiak, Jacek
Sońta-Jakimczyk, Danuta
Chybicka, Alicja
Powiązania:
https://bibliotekanauki.pl/articles/1043814.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
P-glycoprotein
acute myeloblastic leukemia
anthracyclines
acute lymphoblastic leukemia
drug resistance
Opis:
Uptake and efflux of two anthracyclines, idarubicin (IDA) and daunorubicin (DNR), was studied in childhood acute leukemia samples. A comparison of IDA and DNR transport phenomena in relation to drug cytotoxicity and expression of P-glycoprotein (PGP) was made. Intracellular content of IDA/DNR was determined by flow cytometry using the fluorescent properties of the drugs. In vitro drug cytotoxicity was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. PGP expression was analysed by flow cytometry. The uptake and efflux rates were non-significantly higher for IDA than DNR. There were no differences between three types of leukemia with respect to drug content during accumulation and retention. After correction for the cell volume, intracellular concentration of both drugs in each moment of uptake and efflux was significantly lower in relapsed ALL and AML samples in comparison with initial ALL cells. Efflux, but not uptake, of both drugs was inversely correlated with PGP expression and IDA, but not DNR, cytotoxicity. The cytotoxicity was correlated with drug accumulation for both drugs and with drug retention for IDA. In conclusion, it seems that (1) intracellular content was related to the lipophilic properties of the drugs rather than to the type of leukemia, (2) decreased intracellular concentration of both drugs might have an impact on compromised therapy results in AML and relapsed ALL children, (3) IDA presents higher cytotoxicity, which possibly might be decreased by the presence of PGP. These results might have a practical impact on the rational design of new chemotherapy protocols.
Źródło:
Acta Biochimica Polonica; 2002, 49, 1; 99-107
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cytotoxic effects of cladribine and tezacitabine toward HL-60.
Autorzy:
Stachnik, Krzysztof
Grieb, Paweł
Skierski, Janusz
Powiązania:
https://bibliotekanauki.pl/articles/1041452.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
tezacitabine
cladribine
flow cytometry
nucleoside analogs
leukemia
HL-60 cells
Opis:
The aim of the study was to determine the relation between the cytotoxic and cytostatic effects of tezacitabine and cladribine on a HL-60 cell line and the time of exposure of cells to these drugs. Cell viability and induction of apoptosis were assessed using flow cytometry methods. Apoptosis was confirmed by direct microscopic observation. Growth inhibition was examined by cell counting. After 24 h incubation tezacitabine was equally or less toxic compared to cladribine. However, toxicity of tezacitabine strongly rose after 48 h incubation leading to massive cell death at doses much lower than those of cladribine. Assessment of the effect of increased exposure time on the clinical efficacy of tezacitabine is indicated.
Źródło:
Acta Biochimica Polonica; 2005, 52, 2; 561-565
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Nursing care of a child with acute lymphoblastic leukemia
Autorzy:
Ślifirczyk, A.
Piszcz, P.
Ślifirczyk, M.
Michalczuk, T.
Urbańczuk, M.
Celiński, M.
Bytys, M.
Domańska, D.
Nikoniuk, M.
Powiązania:
https://bibliotekanauki.pl/articles/1918640.pdf
Data publikacji:
2018
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Acute lymphoblastic leukemia
cancer
care
Opis:
Every year a very large number of children in the world suffer from acute lymphoblastic leukemia, and for years there has been a steady increase in the number of new cases. Acute lymphoblastic leukemia accounts for 75% of leukemia cases in the world. Lymphoblastic leukemia is a cancer disease that originates in B or T cell lymphocytes, which expansion takes place in blood and in the bone marrow. The etiology of the disease is not fully understood because it consists of several factors conditioning its formation. The most important element is the early detection and taking actions resulting in effective disease control through treatment and care of the patient. The nursing process should allow the patient to be involved in and accept the ongoing cancer process, and medical personnel, family and specialists in such fields as psychology and psychiatry should participate.
Źródło:
Progress in Health Sciences; 2018, 8(2); 168-173
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Natural products as potential inhibitors of FLT3 for acute myeloid leukemia: HTVS, docking, and molecular dynamic simulation
Autorzy:
Salah, Salsabeel
Sami, Najat
Ali, Sarah
Khalid, Teemah-Alrahman
Alnajjar, Radwan
Powiązania:
https://bibliotekanauki.pl/articles/35500319.pdf
Data publikacji:
2023
Wydawca:
Radomskie Towarzystwo Naukowe
Tematy:
acute myeloid leukemia
drug design
anticancer
CADD
FLT3
ostra białaczka szpikowa
projektowanie leków
terapia antynowotworowa
Opis:
Cancer is one the most common health issues worldwide, with cancer-related mortality of 9.5 million in 2018, with an expectation to become 29.5 by 2040. Among others, acute myeloid leukemia (AML) is common among older people. FLT3 mutations are one of the most common genetic aberrations found in Acute Myeloid Leukemia and are associated with poor prognosis. Herein, we attempt to identify natural compounds as potential candidates to treat AML by targeting the FLT3 kinase domain using in silico approaches. The COCONUT database, which contains 407,270 natural compounds, was HTVS against the FLT3 kinase domain active site, and promising compounds were subject to molecular docking. Finally, frontier compounds were validated further using molecular dynamic simulation. In total, ten compounds were identified with docking scores higher than Quizartinib (-11.606 kcal/mol), with the best three compounds showing a docking score of -18.052, -15.772, and -16.767 kcal, respectively, and compound 2 showing excellent stability in molecular dynamic simulation.
Źródło:
Scientiae Radices; 2023, 2, 4; 325-346
2956-4808
Pojawia się w:
Scientiae Radices
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 49

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies